Review





Similar Products

bath applied tram34  (Alomone Labs)
94
Alomone Labs bath applied tram34
Bath Applied Tram34, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tram34/pm41634942-74-0-4?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
bath applied tram34 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
tram34  (MedChemExpress)
94
MedChemExpress tram34
Tram34, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tram34/pm40758224-104-4-7?v=MedChemExpress
Average 94 stars, based on 1 article reviews
tram34 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
tram34  (Wulff labs)
90
Wulff labs tram34
Tram34, supplied by Wulff labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tram34/pm40373182-57-0-5?v=Wulff+labs
Average 90 stars, based on 1 article reviews
tram34 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
tram34  (Alomone Labs)
94
Alomone Labs tram34
Tram34, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tram34/pmc10622898__pnas__2300095120__sapp-13-22-17?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
tram34 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
tram34  (Tocris)
94
Tocris tram34
( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and <t>TRAM34</t> (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
Tram34, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tram34/pmc12162887-44-0-2?v=Tocris
Average 94 stars, based on 1 article reviews
tram34 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
ik1 specific inhibitor tram34  (Alomone Labs)
94
Alomone Labs ik1 specific inhibitor tram34
( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and <t>TRAM34</t> (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
Ik1 Specific Inhibitor Tram34, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tram34/10__1097_slash_aln__0000000000005171-73-25-29?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
ik1 specific inhibitor tram34 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
tram34  (Danaher Inc)
86
Danaher Inc tram34
( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and <t>TRAM34</t> (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
Tram34, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tram34/pm38290177-74-18-24?v=Danaher+Inc
Average 86 stars, based on 1 article reviews
tram34 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and TRAM34 (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).

Journal: EMBO Molecular Medicine

Article Title: A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities

doi: 10.1038/s44321-025-00237-z

Figure Lengend Snippet: ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and TRAM34 (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).

Article Snippet: TRAM34 , Tocris , #2946.

Techniques: Fluorescence, Inhibition, Viability Assay, Derivative Assay